Processa exec buys 1,545 PCSA shares at $2.97
Processa Pharmaceuticals director and Pres.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Processa Pharmaceuticals director and Pres. Research & Development David Young reported an open-market purchase of 1,545 shares of common stock at $2.97 per share on April 15, 2026. After this trade, he holds 12,107 shares directly, plus indirect holdings of 1,242 shares via the Young-Plaisance Revocable Trust, 432 shares via family entities, and 742 shares via CorLyst, LLC.
Insider Trade Summary
Net Buyer: 1,545 shares
Net Buy
4 txns
Insider
Young David
Role
Pres. Research & Development
Bought
1,545 shs ($5K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 1,545 | $2.97 | $5K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 12,107 shares (Direct);
Common Stock — 1,242 shares (Indirect, By Young-Plaisance Revocable Trust);
Common Stock — 432 shares (Indirect, By Family Entities);
Common Stock — 742 shares (Indirect, By CorLyst, LLC)
Key Figures
Open-market purchase: 1,545 shares
Purchase price: $2.97 per share
Direct holdings after trade: 12,107 shares
+3 more
6 metrics
Open-market purchase
1,545 shares
Common Stock bought at $2.97 on April 15, 2026
Purchase price
$2.97 per share
Open-market buy of Processa Pharmaceuticals common stock
Direct holdings after trade
12,107 shares
Common Stock directly owned following April 15, 2026 purchase
Trust holdings
1,242 shares
Indirect ownership by Young-Plaisance Revocable Trust
Family entities holdings
432 shares
Indirect ownership by family entities
CorLyst, LLC holdings
742 shares
Indirect ownership by CorLyst, LLC
Key Terms
open-market purchase, indirect ownership, revocable trust, Form 4, +1 more
5 terms
open-market purchase financial
"reported an open-market purchase of 1,545 shares of common stock"
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
indirect ownership financial
"indirect holdings of 1,242 shares via the Young-Plaisance Revocable Trust"
revocable trust financial
"1,242 shares via the Young-Plaisance Revocable Trust"
A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.
Form 4 regulatory
"The Form 4 shows an open-market purchase of 1,545 shares"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
common stock financial
"purchase of 1,545 shares of common stock at $2.97 per share"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did PCSA executive David Young report on this Form 4?
David Young reported an open-market purchase of 1,545 shares of Processa Pharmaceuticals common stock. The shares were bought at $2.97 per share on April 15, 2026, increasing his directly held ownership stake in the company.
What indirect Processa Pharmaceuticals (PCSA) holdings are associated with David Young?
Indirect holdings associated with David Young include 1,242 shares held by the Young-Plaisance Revocable Trust, 432 shares held by family entities, and 742 shares held by CorLyst, LLC. These positions are reported as indirect ownership on the Form 4.
What is David Young’s role at Processa Pharmaceuticals (PCSA)?
David Young is both a director and the Pres. Research & Development at Processa Pharmaceuticals. His dual role as officer and director is disclosed in the Form 4 reporting his recent open-market share purchase.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates